Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 42, Issue SUPPL. 2, 2008, Pages

  Claviez, A ^a   Sureda, A ^b   Schmitz, N ^c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c DEPARTMENT OF CARDIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ATTRIBUTABLE RISK; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BEAM THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHILD CARE; CHILDHOOD CANCER; DISEASE FREE SURVIVAL; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LYMPHOMA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; RISK FACTOR; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT RESPONSE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK FACTORS; SALVAGE THERAPY; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 55849105951     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.278     Document Type: Review

References (66)

1. Schellong G, Pötter R, Brämswig J, Wagner W, Prott FJ, Dörffel W et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease:tHe German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999; 17: 3736-3744.
2. Dörffel W, Lüders H, Rühl U, Albrecht M, Marciniak H, Parwaresch R et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents:aNalysis and outlook. Klin Pädiatr 2003; 215: 139-145.
3. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002; 20: 3765-3771.
4. Landman-Parker J, Pacquement H, Leblanc T, Habrand JL, Terrier-Lacombe MJ, Bertrand Y et al. Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000; 18: 1500-1507.
5. Schellong G, Riepenhausen M, Creutzig U, Ritter J, Harbott J, Mann G et al. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group. J Clin Oncol 1997; 15: 2247-2253.
6. Schellong G. The balance between cure and late effects in childhood Hodgkin's lymphoma: The experience of the German-Austrian Study-Group since 1978. German-Austrian Pediatric Hodgkin's Disease Study Group. Ann Oncol 1996; 7 (Suppl 4):67-72.
7. Balwierz W, Armata J, Moryl-Bujakowska A, Depowska T, Radwanska U, Kaczarerk M et al. Results of treatment of 36 children with Hodgkin's disease relapsed after initial MVPP chemotherapy and involved field irradiation: A report from the Polish Pediatric Leukemia/Lymphoma Study Group. Pediatr Rev Commun 1992; 6: 153-159.
8. Schellong G, Hörnig-Franz I. Salvage therapy results in childhood Hodgkin's disease. In: Zander A, Barlogie B (eds). Autologous Bone Marrow Transplantation for Hodgkin's Disease, Non-Hodgkin's Lymphoma and Multiple Myeloma. Springer: Berlin Heidelberg, 1993, pp 8-10.
9. Schellong G, Dörffel W, Claviez A, Körholz D, Mann G, Scheel-Walter HG et al. Salvage therapy of progressive and recurrent Hodgkin's disease: Results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005; 23: 6181-6189.
10. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ. Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 1997; 89: 814-822.
11. Anselmo AP, Meloni G, Cavalieri E, Proia A, Enrici RM, Funaro D et al Conventional salvage chemotherapy vs high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients. Ann Hematol 2000; 79: 79-82.
12. Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M et al. Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 1999; 17: 222-229.
13. Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O et al Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 2002; 20: 467-475.
14. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20: 221-230.
15. Josting A, Rueffer U, Franklin J, Sieber M, Diehl V, Engert A. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: A report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96: 1280-1286.
16. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al. Dose intensification with autologous bonemarrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
17. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002; 359: 2065-2071.
18. Schmitz N, Haverkamp H, Josting A, Diehl V, Pfistner B, Carella A et al. Long term follow up in relapsed Hodgkin's disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). J Clin Oncol 2005; 23: 6508 (abstract).
19. Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della VA et al. High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 1999; 17: 3101-3109.
20. Majhail NS, Weisdorf DJ, Defor TE, Miller JS, McGlave PB, Slungaard A et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006; 12: 106 5-1072.
21. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 1997; 89: 801-813.
22. Schmitz N, Glass B, Dreger P, Haferlach T, Horst HA, Ollech-Chwoyka J et al. High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's disease. Ann Hematol 1993; 66 251-256.
23. Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, Yahalom J et al. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2003; 32: 673-679.
24. Matsuzaki A, Okamura J, Nagatoshi Y, Kai T, Ohga S, Gondo H et al. Treatment of young relapsed Hodgkin's disease patients with high-dose chemotherapy followed by peripheral blood stem cell transplantation. Leuk Lymphoma 1995; 18: 505-509.
25. Galvao de Castro Jr C, Gregianin LJ, Brunetto AL. Autologous hematopoietic stem cell transplantation in children with relapse or refractory Hodgkin disease. J Pediatr Hematol Oncol 2006; 28 772.
26. Williams CD, Goldstone AH, Pearce R, Green S, Armitage JO, Carella A et al. Autologous bone marrow transplantation for pediatric Hodgkin's disease: A casematched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry. J Clin Oncol 1993; 11: 2243-2249.
27. Baker KS, Gordon BG, Gross TG, Abromowitch MA, Lyden ER, Lynch JC et al. Autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in children and adolescents. J Clin Oncol 1999; 17: 825-831.
28. Stoneham S, Ashley S, Pinkerton CR, Wallace WH, Shankar AG, United Kingdom Children's Cancer Study Group.. Outcome after autologous hemopoietic stem cell transplantation in relapsed or refractory childhood Hodgkin disease. J Pediatr Hematol Oncol 2004; 26: 740-745.
29. Frankovich J, Donaldson SS, Lee Y, Wong RM, Amylon M, Verneris MR. High-dose therapy and autologous hematopoietic cell transplantation in children with primary refractory and relapsed Hodgkin's disease: A topy predicts idiopathic diffuse lung injury syndromes. Biol Blood Marrow Transplant 2001; 7: 49 -57.
30. Verdeguer A, Pardo N, Madero L, Martinez A, Bureo E, Fernández JM et al. Autologous stem cell transplantation for advanced Hodgkin's disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transplant 2000; 25: 31-34.
31. Lieskovsky YE, Donaldson SS, Torres MA, Wong RM, Amylon MD, Link MP et al. High-dose therapy and autologous hematopoietic stem-cell transplantation for recurrent or refractory pediatric Hodgkin's disease: results and prognostic indices. J Clin Oncol 2004; 22: 4532-4540.
32. Claviez A, Kabisch H, Suttorp M, Gruhn B, Peters C, Bader P et al. The impact of disease status at transplant and time to first relapse on outcome in children and adolescents with relapsed Hodgkin's lymphoma undergoing autologous stem cell transplantation. Bone Marrow Transplant 2005; 35 (Suppl 2): S85.
33. Petropoulos D, Worth LL, Mullen CA, Lockhart S, Choroszy M, Chan KW. Interferon-alpha after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma. Bone Marrow Transplant 2006; 38: 345-349.
34. Harris RL, Termuelin A, Cairo MS, Perkins SL, Gross TG, Warkentin P et al. Safety and efficacy of CBV followed by autologous PBSC transplant in children with lymphoma after failed induction or first relapse - a Children's Oncology Group Study. Pediatr Blood Cancer 2006; 46: 843 (abstract).
35. Constans M, Sureda A, Terol MJ, Arranz R, Caballero MD, Iriondo A et al. Autologous stem cell transplantation for primary refractory Hodgkin's disease: Results and clinical variables affecting outcome. Ann Oncol 2003; 14: 745-751.
36. Czyz J, Szydlo R, Knopinska-Posluszny W, Hellmann A, Gozdzik J, Hansz J et al. Treatment for primary refractory Hodgkin's disease: A comparison of high-dose chemotherapy followed by ASCT with conventional therapy. Bone Marrow Transplant 2004; 33: 1225-1229.
37. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ et al. Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 1999; 17: 534-545.
38. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J et al. Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 2004; 124 645-652.
39. Perry AR, Peniket AJ, Watts MJ, Leverett D, Goldstone AH, Linch DC et al. Peripheral blood stem cell vs autologous bone marrow transplantation for Hodgkin's disease: Equivalent survival outcome in a single-centre matched-pair analysis. Br J Haematol 1999; 105 280-287.
40. Sperotto A, Zaja F, Damiani D, Patriarca F, Fanin R. High-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's lymphoma: A single center experience. Haematologica 2001; 86 1317-1318.
41. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, García-Conde J et al. Autologous stem-cell transplantation for Hodgkin's disease: Results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 2001; 19: 1395-1404.
42. Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ et al. Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005; 16: 625-633.
43. Brandwein JM, Callum J, Sutcliffe SB, Scott JG, Keating A. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 1990; 5: 99-103.
44. Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J et al Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer 1996; 78: 1293-1299.
45. Sureda A, Schmitz N. Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies. Ann Hematol 2003; 82: 1-13.
46. Laurence AD, Goldstone AH. High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma. Semin Hematol 1999; 36 303-312.
47. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996; 14: 572-578.
48. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996; 14: 1291-1296.
49. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol 1993; 11: 2342-2350.
50. Appelbaum FR, Sullivan KM, Thomas ED, Buckner CD, Clift RA, Deeg HJ et al. Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. J Clin Oncol 1985; 3: 1490-1494.
51. Jones RJ, Ambinder RF, Piantadosi S, Santos GW. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
52. Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001; 19: 4314-4321.
53. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: A report of the International Bone Marrow Transplant Registry. Blood 2004; 104: 3797-3803.
54. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, de Elvira CR et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310-4316.
55. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: Low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005; 35: 943-951.
56. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D et al Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005; 365 1934-1941.
57. Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano-Ispizua A et al. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. Br J Haematol 2007; 139: 70-80.
58. Sureda A. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma. Hematol Oncol Clin North Am 2007; 21: 943-960.
59. Alvarez I, Sureda A, Caballero MD, Urbano-Ispizua A, Ribera JM, Canales M et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: Results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006; 12: 172-183.
60. Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2007; 26: 455-462.
61. Schmitz N, Dreger P, Glass B, Sureda A. Allogeneic transplantation in lymphoma: Current status. Haematologica 2007; 92: 1533-1548.
62. Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S et al. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 2000; 26: 615-620.
63. Claviez A, Klingebiel T, Beyer J, Nürnberger W, Ehninger G, Suttorp M et al. Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease. Ann Hematol 2004; 83: 237-241.
64. Bradley MB, Cairo MS. Stem cell transplantation for pediatric lymphoma: past, present and future. Bone Marrow Transplant 2008; 41: 149-158.
65. Claviez A, Canals C, Boogaerts M, Stein J, Mackinnon S, Martino R et al. The impact of allogeneic hematopoietic stem cell transplantation in children and adolescents with recurring Hodgkin's lymphoma: An EBMT study on 151 patients. Blood 2007; 110 (Suppl): 900 (abstract).
66. Körholz D, Claviez A, Hasenclever D, Kluge R, Hirsch W, Kamprad F et al. The concept of the GPOH-HD 2003 therapy study for pediatric Hodgkin's disease: Evolution in the tradition of the DAL/GPOH studies. Klin Pädiatr 2004; 216: 150-156.